SBIR-STTR Award

Analysis Tools for Detection and Diagnosis of Biological Threats
Award last edited on: 2/22/2007

Sponsored Program
SBIR
Awarding Agency
DOD : CBD
Total Award Amount
$849,458
Award Phase
2
Solicitation Topic Code
CBD04-113
Principal Investigator
Hong Dang

Company Information

Alpha-Gamma Technologies Inc

3301 Benson Drive Suite 535
Raleigh, NC 27609
   (919) 954-0033
   agti@alpha-gamma.com
   www.alpha-gamma.com
Location: Single
Congr. District: 04
County: Wake

Phase I

Contract Number: ----------
Start Date: ----    Completed: ----
Phase I year
2004
Phase I Amount
$99,731
DNA microarray technology, in combination with statistical and predictive modeling tools, could be used to evaluate thousands of genes against distinct gene expression patterns induced by chemical/biological agents to provide early identification and speed therapeutic intervention. The overall objective of this proposal is to demonstrate the feasibility of building a data management system for DNA microarray study data with integrated computational analysis tools that can provide identification of chemical and biological threats on the basis of host gene response. Alpha-Gamma proposes to accomplish these objectives by first building and populating a prototype relational database with several sets of DNA microarray data along with pathological and physiological endpoints. Alpha-Gamma will build a web-based user interface to browse and select data for analysis, and integrate established statistical tools (e.g., SAS, S-Plus, Spotfire, Patek) into this user friendly environment. With this integration of statistical tools, Alpha-Gamma will perform normalization of microarray data sets, cluster analysis, and pattern recognition. Alpha-Gamma will also validate the potential of this approach for identifying unknown agents by reserving known samples from the datasets and applying statistical tools to identify best match and confidence level

Phase II

Contract Number: ----------
Start Date: ----    Completed: ----
Phase II year
2004
Phase II Amount
$749,727
DNA microarray technology, in combination with statistical and predictive modeling tools, could be used to evaluate thousands of genes against distinct gene expression patterns induced by chemical/biological agents to provide early identification and speed therapeutic intervention. The overall objective of this Phase II effort is to leverage existing public domain resources and commercial tools to provide the Army with a comprehensive data management system with integrated statistical and pattern recognition tools capable of: 1) Identifying agent specific gene profile biomarker signatures; 2) Teasing out exogenous factors such as ingested food, stressors, etc.; 3) Discriminating naturally occurring diseases from weaponized biological agents; and 4) Linking gene expression responses to physiological responses. Similar needs for a data management system with statistical and visualization tools exists in the private sector, specifically basic research and the pharmaceutical industry. The secondary objective of Phase II is to develop a product that meets private sector needs as well as those of the Army. At the conclusion of Phase II, Alpha-Gamma will have a product (bioCAT) ready for commercialization in the private sector. MICROARRAY ANALYSIS, BIOINFORMATICS, DETECTION OF CHEMICAL AND BIOLOGICAL AGENTS